Results 91 to 100 of about 68,267 (269)
High-levelexpression of functional recombinant human coagulation factor VII in insect cells [PDF]
: Recombinant coagulation factor VII (FVII) is used as a potential therapeutic intervention in hemophilia patients who produce antibodies against the coagulation factors.
AD Shapiro +30 more
core +1 more source
ABSTRACT Introduction Bleeding episodes can impair physical functioning and cause chronic pain in haemophilia A. The Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL) was administered in XTEND‐1; the Physical Health (PH) subscale evaluated Physical Health/Functioning. Aim To evaluate psychometric properties of Haem‐A‐QoL PH and estimate
Jérôme Msihid +6 more
wiley +1 more source
Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders
ABSTRACT Introduction Joint bleeds are burdensome and recovery differs from bleed to bleed. Identifying predictors of recovery could enable personalized treatment and monitoring; aiming to prevent long‐term joint deterioration, and facilitate faster return to activities. Aim To identify predictors of time to recovery after joint bleeding in people with
Gijs Aertssen +4 more
wiley +1 more source
Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality [PDF]
Importance: Despite the absence of data from randomized clinical trials, professional societies recommend inferior vena cava (IVC) filters for patients with venous thromboembolic disease (VTE) and a contraindication to anticoagulation therapy.
Brown, David L +3 more
core +1 more source
Gene Editing for Haemophilia—The Next Frontier
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti +3 more
wiley +1 more source
Algorithms of hemostatic therapy of hemophilia disease are presented.The treatment is based onsubstitute therapy by blood clotting factorsand other hemostatic drugs. Schemes for calculationof the hemostaticdrug doses, intervals between the doses, and duration of treatment forthe mostincident manifestations of the hemorrhagic syndrome arepresented ...
null С. В. Видиборець +2 more
openaire +2 more sources
ABSTRACT Objective This study aimed to evaluate the obstetric management, complications and clinical characteristics of pregnant women diagnosed with hereditary coagulation factor deficiencies at a tertiary obstetric centre over a 10‐year period. Methods We retrospectively reviewed a total of 19 pregnancies in 17 women with hereditary coagulation ...
Melis Altug Inan +3 more
wiley +1 more source
Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia
ABSTRACT Introduction Clotting factor prophylaxis remains the most prescribed standard‐of‐care treatment for people with haemophilia (PwH). Prophylaxis prevents bleeds, joint damage, and improves quality of life (QoL). Its success depends on treatment adherence, consisting of socioeconomic, behavioural, and disease‐ or therapy‐related factors.
Nathália Martins Beserra +9 more
wiley +1 more source
Background. Patients with hemophilia should be evaluated for joint health and overall health in their visits. The aims of this study were to evaluate joint health and health-related quality of life (HRQoL) in patients with mild, moderate, and severe ...
Buse Günyel +3 more
doaj +1 more source
ABSTRACT Introduction Recent advances in prophylaxis with clotting factor concentrates have enabled people with haemophilia (PwH) to participate in high‐intensity exercises; however, this does not preclude them from sports‐induced bleeding (SIB). Aim To investigate factors influencing the recent occurrence of SIB among PwH.
Rie Shirayama +3 more
wiley +1 more source

